cyrilzakka/clinical-trials huggingface dataset:
A Study to Quantify Use of Anticoagulation to Improve Management of Atrial Fibrillation

The purpose of this study is to evaluate the impact of a hospital quality improvement (QI) program on the use of guideline-recommended oral anticoagulants (OAC) in hospitalized patients with atrial fibrillation (AF) at risk for ischemic stroke. Specifically, the study will determine whether the intervention, compared to Usual Care, will result in a greater increase in the proportion of patients with AF at risk for ischemic stroke who are appropriately treated with OAC.


Eligibility Criteria:
Inclusion Criteria:

* Inpatient hospitalization
* Primary or secondary discharge International Classification of Diseases (ICD)-9/10 diagnosis code for AF paroxysmal (I48.0), persistent (I48.1), chronic (I48.2), or unspecified (427.31, I48.91)
* Proxied Congestive Heart failure (CHA2DS2-VASC) score greater than or equal to (\>=) 2 using ICD-9 diagnosis scoring algorithm developed previously. The scoring algorithm will be expanded to include ICD-10 codes
* Discharged to home, skilled nursing facility, inpatient rehabilitation, or nursing home

Exclusion Criteria:

* Presence of artificial mechanical heart valve by ICD-9/10 diagnosis or procedure code during comorbid identification period or current hospitalization
* Surgical procedure during hospitalization for open heart surgery, brain, or spine
* Intravenous heparin given on the day of discharge without warfarin/oral anticoagulant (OAC), antiplatelets, and/or aspirin
* History of left atrial appendage occlusion, including the Watchman device
* Any in-hospital (current hospitalization) bleeding identified by ICD-9/10 diagnosis codes
Influence of Food Texture on Appetite Control, Gastric Emptying, and Energy Expenditure

The aim of the study is to investigate the effect of liquid versus semi-solid meals on the regulation of energy balance in healthy young adults.The main questions it aims to answer are:

* Does a protein-rich liquid meal result in less satiety and therefore higher ad libitum energy intake at the next meal than an isocaloric oatmeal with the same macronutrient ratio?
* Is the consumption of a protein-rich liquid meal as a beverage in addition to an ad libitum oatmeal less compensated within the meal and at the next meal and provides thus a higher ad libitum energy intake than an isovolumetric noncaloric soft drink in addition to an ad libitum oatmeal?

Researchers will compare a protein-rich liquid meal to an isocaloric oatmeal with matched macronutrient composition to answer the first question. Researchers will compare a protein-rich liquid meal + oatmeal to a noncaloric softdrink (water with sucralose and flavoring) + oatmeal to answer the second question.

Participants will:

* spend 4 intervention days in a metabolic chamber (whole room indirect calorimeter)
* consume pre-definied preloads for breakfast and ad libitum lunch meals on 4 intervention days


Eligibility Criteria:
Inclusion Criteria:

* healthy males and females
* Body Mass Index between 19-35 kg/m2
* low to medium habitual physical activity
* women with regular menstrual cycle (during intervention in follicular phase)

Exclusion Criteria:

* smoking (cigarettes + cannabis)
* chronic illnesses
* regular intake of medication
* Anemia and/or iron deficiency
* food allergies / intolerances
* vegans
* regular high physical activity (exercise \>1 hour/d)
* current weight loss diet / weight loss of \>5 kg in the last 3 months
* restraint eaters (according to the German version of the 'Three-Factor-Eating-Questionnaire', Stunkard und Messick (1985))
* active participation in another trial
* pregnant / lactating women
* persons incapable of giving informed legal consent
Effectiveness and Safety of Xiaoshuanchangrong (XSCR) Capsule for the Treatment of Patients Who Have Suffered From a Stroke

This study will determine if Xiaoshuanchangrong (XSCR) capsule will improve recovery from an acute stroke. The study is designed to look at both overall recovery and recovery of motor function, for example muscle strength and coordination.


Eligibility Criteria:
Inclusion Criteria:

* Acute ischemic stroke with limb weakness, NIH stroke scale ≥6, limb weakness score ≥2
* Onset of symptoms within 72 hours
* 18 Years and older
* Consistent with the Qi deficiency and Blood stasis type by Traditional Chinese Medicine (TCM) standard
* Patients or their representatives voluntarily take part in this study and signed the informed consent

Exclusion Criteria:

* Transient ischemic attack(TIA), cerebral hemorrhage, subarachnoid hemorrhage
* Subjects who are unlikely to complete taking the investigational product and/or are unlikely to undergo active medical management during that period due to a severe clinical condition.
* Pregnant or breast-feeding.
* Proven disability by law, such as blindness, deafness, dumb, disturbance of intelligence, mental disorders, limb handicap.
* Liable to be allergic (allergic to at lease 2 foods/drugs previously exposed)
* Had been participated in other clinical trials during the last 1 month prior to study inclusion.
COVID Infection in Pediatric Surgical Patient

Children infected with COVID-19 are mostly asymptomatic. There is a dearth of data on the epidemiology of COVID-19 in the pediatric population. This is a prospective observational clinical study of pediatric surgical patients. COVID-19 rapid antigen testing will be performed on pediatric patients.

Children infected with COVID-19 are mostly asymptomatic or mildly symptomatic. Children may spread COVID-19 to the elderly, vulnerable patients and medical staff. There is a dearth of data on the epidemiology of COVID-19 in the pediatric surgical population. Rapid antigen detection tests for the diagnosis of COVID-19 are reliable, simple, fast, and inexpensive.

This is a prospective observational clinical study. The study population will include all consenting pediatric surgical patients, aged 2-17 years. Informed consent will be obtained from each patient and the legal guardian who agree to participate in the study. Nasopharyngeal swab specimens will be collected from anesthetized pediatric patients. COVID-19 rapid antigen testing will be performed according to the equipment manufacturer's instructions.

Data collection will include COVID-19 test result, nasal swab complication, patient demographics, surgical history, medical history, regular medications, COVID-19 symptoms, and COVID-19 exposure information. COVID-19 symptoms that will be recorded are cough, wheeze, nasal congestion, breathing difficulty, new loss of taste or smell, fever, chills, rigors, body aches, sore throat, nausea, and fatigue. COVID-19 exposure will be considered as being within 6 feet of a person with diagnosed COVID-19 infection in the previous 14 days.

Eligibility Criteria:
Inclusion Criteria:

* surgical patients aged 2-17 years
* informed consent for surgery
* no COVID-19 diagnosis in previous 6 months
* no history of nasal bleeding
* no history of coagulopathy.

Exclusion Criteria:

* patient refusal of testing
* difficulty in obtaining consent
* COVID-19 diagnosis in recent 6 month
* history of nasal bleeding
* history of coagulopathy.
Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma

RATIONALE: Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase II trial is studying how well bortezomib works in treating patients with relapsed or refractory cutaneous T-cell lymphoma.

OBJECTIVES:

* Determine the response rates (complete response and partial response) and duration of response in patients with relapsed or refractory cutaneous T-cell lymphoma treated with bortezomib.
* Determine the safety and tolerability of this drug in these patients.

OUTLINE: This is an open-label study.

Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed at 1 month and then at least every 3 months for 2 years or until disease progression.

PROJECTED ACCRUAL: A total of 15-25 patients will be accrued for this study.

Eligibility Criteria:
Inclusion Criteria:

* Histologically confirmed cutaneous T-cell lymphoma, including mycosis fungoides/Sézary syndrome
* Stage IB-IV disease
* Relapsed or refractory disease OR intolerant to ≥ 1 prior systemic therapy
* Measurable disease by radiological imaging or clinical finding
* Age Over 18
* Performance status Karnofsky 70-100%
* Hematopoietic

  * WBC \> 2,000/mm\^3
  * Absolute neutrophil count \> 1,500/mm\^3
  * Platelet count \> 75,000/mm\^3
  * Hemoglobin \> 8.0 g/dL
* Hepatic

  * Bilirubin \< 2 times upper limit of normal (ULN)
  * AST and ALT \< 3 times ULN
* Renal

  * Creatinine \< 1.5 times ULN
  * Creatinine clearance ≥ 30 mL/min
* Negative pregnancy test
* Fertile patients must use effective contraception
* More than 3 months since prior high-dose chemotherapy
* More than 30 days since prior and no other concurrent investigational drugs

Exclusion Criteria:

* history of myelodysplastic syndromes
* evidence of CNS disease
* pregnant or nursing
* peripheral neuropathy ≥ grade 2
* hypersensitivity to bortezomib, boron, or mannitol
* serious medical condition or psychiatric illness that would preclude study participation
* concurrent immunotherapy
* concurrent chemotherapy
* concurrent steroid dose \> 10 mg/day of prednisone or its equivalent
* concurrent radiotherapy
* concurrent surgery for the malignancy
Evaluating Acupuncture Relationship With the Catecholaminergic Pathway

Activation of the sympathetic nervous system attenuates inflammation via catecholamines, recent advances in electroacupuncture allow activating critical neuronal networks with the release of catecholamines the aim of this research was to evaluate de effect of electroacupuncture in the activation of sympathetic nervous system and the control of low back pain in athletes

Activation of the sympathetic nervous system attenuates inflammation via activation of β2-adrenoreceptors by catecholamines, Electrical stimulation of vagus nerve limits the inflammatory response in several animal models of inflammatory diseases, In addition, voluntary activation of the sympathetic nervous system by meditation, training or breathing techniques limits production of proinflammatory cytokines in vivo during experimental endotoxemia in healthy human volunteers.

Currently there are therapies that effectively antagonize proinflammatory cytokines and control pain, as non-steroidal anti-inflammatory drugs and opioid analgesics, but had serious side effects if used chronically. Therefore, alternative therapies as electroacupuncture, which may limit inflammatory cytokine production more physiologically, are warranted. The aim of this study was to evaluate de effect of electroacupuncture used for attenuation of low back pain in the activation of sympathetic nervous system and leukocyte inflammatory potential.

Eligibility Criteria:
Inclusion Criteria:

(Controls)

* Healthy
* Non Smokers
* Athletes

(Cases)

* Acute Low Back Pain (less than 1 month)
* Athletes
* Non Smokers

Exclusion Criteria:

* Sciatic Pain
* Smokers
* Chronic Low Back Pain
Myopia Intervention in Children and Adolescents and Establishment of a Precise Intervention Model

Investigators are going to conduct a multi-centered randomized clinical trial that myopic children are randomly allocated into three groups: 0.01% atropine， 0.04% atropine and orthokeratology in order to evaluate the efficacy and side effects of different intervention methods and establish a risk factor model to predict the efficacy of myopia intervention, and to provide precise intervention plans and clinical decisions for the control of myopia.

Investigators are going to conduct a multi-centered randomized clinical trial that myopic children are randomly allocated into three groups: 0.01% atropine， 0.04% atropine and orthokeratology in order to evaluate the efficacy and side effects of different intervention methods and establish a risk factor model to predict the efficacy of myopia intervention, and to provide precise intervention plans and clinical decisions for the control of myopia.

Eligibility Criteria:
Inclusion Criteria:

* children aged from 8-15 years old;
* children with spherical degree ranged from -1.0D to -4.0D, cylindrical degree less than -1.50D, astigmatism with the rule less than -1.25D, astigmatism with other axial distribution less than -0.50, anisometropia less than -1.50D;
* children with BCVA less than 0.1 LogMAR for both eyes;
* children without other eye diseases except for ametropia

Exclusion Criteria:

* children with other eye diseases: amblyopia, strabismus, eye trauma, etc;
* children with cycloplegia contradictions;
* children who have used atropine or orthokeratology;
* children who are severly allergic with atropine;
* children who are using other eye drops for treatment;
* children who have contraindications to orthokeratology or cannot cooperate with it;
* children with severe heart, lung, liver and kidney diseases
Immediate Loading a Histological Study

Twelve participants with edentulous alveolar crests in the distal portion of the arches will be included in the study. At least two implant sites will be identified in each patient and will be sub-prepared with drills or sonic instruments. One site will be used as a test and one as a control where experimental mini-implants will be installed. Reconstructive surgical procedures will be applied at the biopsy sites.

Objective: - To evaluate histologically the influence of the functional load on implants, both immediate and delayed.

Material and methods: 12 participants with edentulous alveolar crests in the distal portion of the arches will be included in the study. At least two implant sites will be identified in each patient and will be sub-prepared with drills or sonic instruments to obtain a high degree of torque to ensure optimum primary stability. At least one site will be used as a test and one as a control where experimental mini-implants will be installed. Test sites will be loaded immediately. The control sites will remain unloaded. After 2 months, mini-implants will be recovered as planned for each group. Reconstructive surgical procedures will be applied at the biopsy sites, if necessary, using autologous bone or bone substitutes and membranes. Standard implants will be installed during the same surgical session and, after 2 months, the planned prosthesis will be performed. Patients will be followed for at least 2 years for evaluation and intervention, if necessary.

Biopsies will be included in resin to obtain wear cuts for histomorphometric analysis. The bone histomorphometry will be evaluated and statistical analysis will be carried out.

Eligibility Criteria:
Inclusion Criteria:

* Adult participants (≥25 years of age) with the need of at least two implants to replace teeth of the jaw will be included.
* Natural antagonist teeth have to be present both at test and control sites to guarantee occlusal contacts

Exclusion Criteria:

* untreated rampant caries or uncontrolled periodontal disease of the remaining teeth
* diabetes not controlled diabetes or any other systemic or local disease that could compromise postoperative healing and / or osseointegration
* need for systemic corticosteroids or any other medication that could compromise postoperative healing and / or osseointegration
* inability or unwillingness to return to follow-up not likely to be able to comply with the study procedures according to the judgment of the investigators
* pregnancy
Intestinal Metagenome of Undernourished in Patients

The objective of this trial is to evaluate gut microbiota changes in undernourished patients with anorexia nervosa under enteral nutrition.

This is a prospective, comparative, non-interventional study involving one clinical nutrition unit in France. Gut microbial will be evaluated with feces between patients and healthy volunteers.

Main investigations:

* Presence of gut microbial deviation compared to healthy volunteers;
* Presence of a significant statistical association between this deviation and metabolic disorders.

For each patient under the routine care a clinical examination and a blood sample will be done for standard biology report and nutrition. The age, gender, weight, height (for calculation of BMI), type of anorexia nervosa will be also collected with the pathological behavior associated (physical and intellectual hyperactivity, potomania, ongoing supplements drug taking including vitamins and trace elements). Eating and psychological disorders will be evaluated with EDI (eating disorder inventory) questionnaire.

Only the age, gender, height, weight (BMI), medical antecedents and ongoing treatment taking will be collected.

Eligibility Criteria:
Inclusion Criteria:

Patients:

1. Anorexia nervosa as defined by DSM-5 (Diagnostic and Statistics Manual of Mental disorders
2. Undernutrition defined by BMI under 15
3. Age superior to 18
4. Patient hospitalised for undernutrition or seen in hospital day
5. Affiliation to the French social security regime or a similar regime
6. Patient signed informed consent

Healthy volunteers:

1. Age superior to 18
2. Normal weight (BMI 18.5 - 25)
3. Affiliation to the French social security regime or a similar regime
4. Patient signed informed consent

Exclusion Criteria:

Patients:

1. Taking antibiotics two month before hospitalization
2. Purge line with laxative abuse one month before hospitalization
3. Another disease may be associated to microbiota profile modification (diabetes, MICI or digestive organ pathology, metabolic disease)
4. Obesity prior to anorexia nervosa
5. Safeguard justice procedure

Healthy volunteers:

1. Metabolic anomaly
2. Recent weight change
Study Looking at Biomarkers in Ovarian Cancer

This is a sample study that will collect biological samples (blood, tumor tissue, ascites, and/or other fluids) from gynecological cancer patients for biomarker research. In addition, the results of the testing done on the samples will be given to the participant's treating physician who may use the information to guide treatment decisions.


Eligibility Criteria:
Inclusion Criteria:

* Histological diagnosis of stage III or IV high grade serous ovarian, tubal or primary peritoneal cancer.
* Must be 18 years of age or older.
* Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1.
* Have a life expectancy greater than or equal to 6 months.
* Able to provide adequate informed consent.
* Willing to undergo blood or fluid collection and tumour biopsy
* Patients enrolled at the time of surgery must agree to have part of their tumour used for the purpose of the study.
* Archival tissue must be available for patients that are enrolled at the time of progression.

Exclusion Criteria:

* Must not have early stage (I and II) high grade serous, tubal or primary peritoneal cancer.
* Must not have other tumour histology other than high grade serous.
* Must not have contraindication to tumour biopsy and/or blood sampling.
Impact of a Personalized Medication Plan on Duration of Treatment With Potent Opioids in Acute Non-cancer Musculoskeletal Pain.

The aim of this study is to evaluate whether patients who benefit from a personalized pharmaceutical plan (PPP) during their hospitalization, allowing them to be informed and sensitized, are treated for a shorter period of time with strong opioids with a reduced risk of dependence compared to a management according to the usual modalities in the rheumatology services concerned.


Eligibility Criteria:
Inclusion Criteria:

* Patient hospitalized in the rheumatology department
* Patient with acute pain in the context of a non-cancerous, non-traumatic, high-energy musculoskeletal pathology
* Patient for whom a prescription of strong opioid derivatives is initiated in rheumatology or patient for whom a prescription of strong opioid derivatives is maintained in rheumatology if the initial prescription has a maximum duration of 30 consecutive days prior to inclusion

Exclusion Criteria:

* Patient with cancer or fibromyalgia already diagnosed at inclusion
* Patient with poor French language skills
* Taking a strong opioid treatment for more than 30 consecutive days prior to inclusion
* Person judged by the prescriber or pharmacist as not autonomous for the management of strong opioid treatment
* Patient already included in the study
Evaluation of Rapid Diagnosis Tests in Imported Malaria

The annual number of cases of clinical malaria worldwide is estimated to be 300-500 million leading to 1.5 million deaths. Delayed care and frequent drug resistance of Plasmodium falciparum (Pf), the most frequent form of malaria, is responsible for these deaths. Each year, 5000-8000 travellers return to France with malaria, 4/5 from Africa and with Pf. Clinical features associated with a malaria crisis are poorly predictive and misdiagnosis can be easily made. Diagnosis of accurate malaria rely on microscopic examination of stained thin and thick blood films by a well trained microscopist. Few emergency wards are specialized for tropical diseases. For most of them, malaria is a rare disease and hours are lost before accurate microscopy can permit the decision

The annual number of cases of clinical malaria worldwide is estimated to be 300-500 million leading to 1.5 million deaths. Delayed care and frequent drug resistance of Plasmodium falciparum (Pf), the most frequent form of malaria, is responsible for these deaths. Each year, 5000-8000 travellers return to France with malaria, 4/5 from Africa and with Pf. Clinical features associated with a malaria crisis are poorly predictive and misdiagnosis can be easily made. Diagnosis of accurate malaria rely on microscopic examination of stained thin and thick blood films by a well trained microscopist. Few emergency wards are specialized for tropical diseases. For most of them, malaria is a rare disease and hours are lost before accurate microscopy can permit the decision The rapid diagnostic tests (RDT) for malaria are designed to give a sensitive response within 15 minutes. They are based on the immunodetection of HISTIDIN rich protein 2 (HRP2) or the Pf LACTICO dehydrogenase (PfLDH), specific of Plasmodium falciparum or plasmodial LACTICO dehydrogenase (pLDH), or aldolase, specific of gender of the four species of human malaria. Recent increase of performances and availability prompted WHO to recommend their use for the diagnosis of malaria when microscopy is unavailable. In France, competence exists on the whole of the territory but expertise is usually confined to major referral centers. We intend to evaluate the performances of 4 RDT in 6 laboratories who perform the diagnosis of malaria on patients samples who returned from tourist or family or professional trips. The simultaneous detection of the plasmodial HRP2, PfLDH, aldolase and pLDH will be compared with the thick blood film as reference. Discrepant results will be analysed by PCR. The determination of the sensitivity, the specificity, the predictive positive value and the predictive negative value of the RDT is the principal objective.

Eligibility Criteria:
Inclusion Criteria:

* No refusal by patient
* Sample for malaria diagnosis

Exclusion criteria:

* Patient who do not want to participated to the study